Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Stryker Corporation (SYK) — XLV Health Care · S&P 500 Profile |史賽克介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Stryker Corporation (SYK) — Business, History & S&P 500 Profile |史賽克介紹

Stryker Corporation company profile · MedSurg and neurotechnology, orthopaedics, Mako robotics · history · financial snapshot · S&P 500 rank #99 · 史賽克公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 29, 2026 (frozen benchmark)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$119.58B
Oct 29, 2026 (frozen benchmark)
S&P 500 WEIGHT
0.17%
Rank #99 · Oct 29, 2026 (Slickcharts)
FY2025 NET SALES
$25.12B
+11% YoY · year ended Dec 31, 2025
FY2025 NET EARNINGS
$3.25B
Diluted EPS $8.40 (vs $7.76)

SNAPSHOT

TickerSYK (NYSE)
CompanyStryker Corporation (stryker.com)
GICS sector / industryHealth Care (XLV) / Health Care Equipment & Supplies
S&P 500 rank (by weight)#99 · 0.17% (Oct 29, 2026)
Sector rank (by market cap)#16 in Health Care (Oct 29, 2026)
HeadquartersPortage, Michigan, USA
Founded1941 in Kalamazoo, Michigan (incorporated in Michigan in 1946)
CEOKevin A. Lobo, chair and chief executive officer
EmployeesAbout 56,000 worldwide (Dec 31, 2025)
Market cap$119.58B (Oct 29, 2026, frozen benchmark)
SEC filingsSEC EDGAR — CIK 0000310764

WHAT IT DOES

Stryker Corporation is a medical technology company that makes surgical equipment, neurotechnology products and orthopaedic implants, and provides related services. Its products are sold in about 61 countries, and the United States accounted for $19.01B, or 76%, of fiscal 2025 net sales.

The business has two segments. MedSurg and Neurotechnology ($15.65B in fiscal 2025) covers surgical equipment, endoscopy, patient handling, emergency medical equipment and neurotechnology, including the Mako robotic-arm system. Orthopaedics ($9.47B) covers implants for hip, knee, shoulder, spine and trauma surgery.

Stryker sells capital equipment, implants and disposables together: the Mako installed base and the surgical equipment fleet pull through high-margin implant and service revenue. Growth comes from new products, robotic adoption, acquisitions — Inari Medical closed in February 2025 for $4.9B — and expansion in emerging markets.

BUSINESS SEGMENTS — FY2025 REVENUE

SegmentRevenueShareYoY
MedSurg and Neurotechnology$15.65B62.3%+15.7%
Orthopaedics$9.47B37.7%+4.3%
Total$25.12B100%+11.2%
Source: Stryker FY2025 Form 10-K, segment note, as reported. In 2026 Stryker reorganised its businesses (Ortho Tech) and recast the 2023–2025 segment presentation in a June 26, 2026 8-K; the figures above are the as-reported 10-K presentation.

HISTORY

YearMilestone
1941Dr. Homer H. Stryker founds the business in Kalamazoo, Michigan.
1946The company is incorporated in Michigan.
1979Stryker completes its initial public offering.
1998Stryker acquires Howmedica, expanding into orthopaedic implants.
2012Kevin Lobo becomes chief executive officer.
2013Stryker acquires Mako Surgical, entering robotic-arm assisted surgery.
2016Stryker acquires Sage Products, adding patient-handling products.
2022Stryker acquires Vocera, adding clinical communication technology.
2025Stryker acquires Inari Medical for $4.9B, closing in February 2025.
2025Stryker divests its US spinal implants business to VB Spine.
2026Stryker creates the Ortho Tech business and recasts its segment presentation (June 26, 2026 8-K).

COMPETITIVE POSITION

  • Scale in medtech. One of the largest medical device companies by revenue, with breadth across the operating room that few rivals match.
  • Mako robotics. The Mako system is a differentiator in joint replacement, driving implant share where hospitals adopt the platform.
  • Innovation cadence. A steady stream of new products in endoscopy, neurotechnology and orthopaedics supports pricing and share gains.
  • Acquired growth. Deals such as Mako (2013), Vocera (2022) and Inari (2025) have added new product lines and sales channels.
  • Competition. Large diversified medtech rivals (Medtronic, Johnson & Johnson MedTech, Zimmer Biomet) and specialised players compete on technology, clinical evidence and price.

FINANCIAL SNAPSHOT — FY2025

Net sales$25.12B (+11.2% YoY)
Gross profit$16.07B (64.0% of sales)
Operating income$4.90B (19.5% of sales)
Net earnings$3.25B (+8.5% YoY)
Diluted EPS$8.40 (vs $7.76 in FY2024)
Total assetsNot available
Total shareholders' equityNot available
Source: Stryker FY2025 Form 10-K and Q4/FY2025 results release (January 29, 2026). Reported margins: gross 64.0%, operating 19.5%; gross profit and operating income are derived from those margins applied to $25,116M net sales.

KEY RISKS

  • Hospital capital budgets. A large share of revenue depends on hospitals' willingness to buy capital equipment, which tightens when budgets or reimbursement fall.
  • Supply chain and tariffs. Components, sterilisation and logistics costs, plus tariffs on imported goods, can pressure the 64.0% gross margin.
  • Acquisition integration. The Inari deal and the 2026 Ortho Tech reorganisation require execution; large deals carry goodwill and integration risk.
  • Regulation and product liability. Devices are regulated by the FDA and other agencies; recalls, safety issues or litigation can be costly.
  • Currency and pricing. About 24% of sales are outside the US, and hospital purchasing organisations negotiate prices aggressively.

WHY IT MATTERS FOR THE S&P 500

At #99 by weight and #16 in Health Care, Stryker is a core holding in the health care sleeve and a proxy for hospital capital spending and orthopaedic procedure volumes.

Its mix of capital equipment, implants and disposables gives the index exposure to both hospital investment cycles and ageing-driven procedure demand, two of the sector's main growth drivers.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by Weight snapshot, as of Oct 29, 2026 close (frozen benchmark per Jazz verdict doc 1514); price $311.75, rank #99, weight 0.17%, market cap $119.58B.
FinancialsStryker FY2025 Form 10-K (fiscal year ended Dec 31, 2025; filed February 11, 2026) and Q4/FY2025 results release (January 29, 2026).
Sector classificationGICS Health Care / Health Care Equipment & Supplies; XLV.
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

STRYKER

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼SYK(紐約證券交易所)
公司Stryker Corporation(stryker.com)
GICS 板塊/行業醫療保健(XLV)/醫療保健設備與用品
標普500排名(按權重)#99 · 0.17%(2026 年 10 月 29 日)
板塊內排名(按市值)醫療保健第 16 名(2026 年 10 月 29 日)
總部美國密歇根州波蒂奇
成立1941 年,美國密歇根州卡拉馬祖(1946 年於密歇根州註冊成立)
行政總裁Kevin A. Lobo,董事長兼行政總裁
員工全球約 56,000 人(2025 年 12 月 31 日)
市值$119.58B(2026 年 10 月 29 日,凍結基準)
SEC 申報SEC EDGAR — CIK 0000310764

業務概覽

史賽克公司是一間醫療科技公司,生產手術設備、神經技術產品與骨科植入物,並提供相關服務。產品銷往約 61 個國家;美國佔 2025 財年淨銷售額 $19.01B,即 76%。

業務分為兩個板塊。醫療外科與神經技術(2025 財年 $15.65B)涵蓋手術設備、內窺鏡、病人搬運、急救醫療設備及神經技術,包括 Mako 機械臂系統。骨科($9.47B)涵蓋髖、膝、肩、脊柱及創傷手術植入物。

史賽克將資本設備、植入物與耗材一併銷售:Mako 裝機量與手術設備機隊帶動高利潤的植入物與服務收入。增長來自新產品、機械人普及、收購——Inari Medical 於 2025 年 2 月以 $4.9B 完成收購——以及新興市場擴張。

業務板塊 — FY2025 收入

SegmentRevenueShareYoY
醫療外科與神經技術$15.65B62.3%+15.7%
骨科$9.47B37.7%+4.3%
合計$25.12B100%+11.2%
來源:史賽克 2025 財年 10-K 表格板塊附註(按報告口徑)。2026 年史賽克重組業務(Ortho Tech)並於 2026 年 6 月 26 日 8-K 表格重述 2023–2025 年板塊呈列;上表為 10-K 報告口徑。

歷史沿革

YearMilestone
1941Homer H. Stryker 醫生於密歇根州卡拉馬祖創辦業務。
1946公司於密歇根州註冊成立。
1979史賽克完成首次公開發售。
1998史賽克收購 Howmedica,擴展至骨科植入物。
2012Kevin Lobo 出任行政總裁。
2013史賽克收購 Mako Surgical,進軍機械臂輔助手術。
2016史賽克收購 Sage Products,新增病人搬運產品。
2022史賽克收購 Vocera,新增臨床通訊技術。
2025史賽克以 $4.9B 收購 Inari Medical,於 2025 年 2 月完成。
2025史賽克將美國脊柱植入物業務出售予 VB Spine。
2026史賽克成立 Ortho Tech 業務並重述板塊呈列(2026 年 6 月 26 日 8-K 表格)。

競爭地位

  • 醫療科技規模。按收入計為最大的醫療器械公司之一,手術室產品廣度少有對手可比。
  • Mako 機械人。Mako 系統是關節置換的差異化優勢,在醫院採用該平台的地方帶動植入物份額。
  • 創新節奏。內窺鏡、神經技術與骨科新產品源源不斷,支撐定價與份額增長。
  • 收購增長。Mako(2013 年)、Vocera(2022 年)及 Inari(2025 年)等交易新增產品線與銷售渠道。
  • 競爭。大型綜合醫療科技對手(Medtronic、Johnson & Johnson MedTech、Zimmer Biomet)及專業公司在技術、臨床證據與價格上競爭。

財務快照 — FY2025

淨銷售額$25.12B(+11.2% YoY)
毛利$16.07B(佔銷售額 64.0%)
經營收入$4.90B(佔銷售額 19.5%)
淨利潤$3.25B(+8.5% YoY)
稀釋每股盈利$8.40(2024 財年為 $7.76)
總資產暫無資料
股東權益總額暫無資料
來源:史賽克 2025 財年 10-K 表格及 2025 財年第四季業績公告(2026 年 1 月 29 日)。報告利潤率:毛利率 64.0%,經營利潤率 19.5%;毛利與經營收入由該等利潤率乘以 $25,116M 淨銷售額推算。

主要風險

  • 醫院資本預算。大比例收入取決於醫院購買資本設備的意願,預算或報銷收緊時即受影響。
  • 供應鏈與關稅。零部件、滅菌與物流成本,加上進口商品關稅,可能壓縮 64.0% 的毛利率。
  • 收購整合。Inari 交易與 2026 年 Ortho Tech 重組均需執行;大型交易帶有商譽與整合風險。
  • 監管與產品責任。器械受 FDA 及其他機構監管;召回、安全問題或訴訟可能代價高昂。
  • 匯率與定價。約 24% 銷售額來自美國以外,醫院採購組織議價積極。

對標普500的重要性

按權重計排名 #99、醫療保健板塊第 16 名,史賽克是醫療保健板塊的核心持股,也是醫院資本開支與骨科手術量的代表。

其資本設備、植入物與耗材組合,使指數同時受惠於醫院投資週期與老齡化帶動的手術需求——這是該板塊的兩大增長動力。

來源與方法

市場數據Slickcharts 標普500按權重快照,截至 2026 年 10 月 29 日收市(按 Jazz 裁決文件 1514 的凍結基準);股價 $311.75,排名 #99,權重 0.17%,市值 $119.58B。
財務數據史賽克 2025 財年 10-K 表格(財年截至 2025 年 12 月 31 日;2026 年 2 月 11 日提交)及 2025 財年第四季業績公告(2026 年 1 月 29 日)。
板塊分類GICS 醫療保健/醫療保健設備與用品;XLV。
資料庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

STRYKER

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · SYK
Data as of Oct 29, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Salesforce, Inc. (CRM) — XLK Information Technology · S&P 500 Profile |賽富時公司介紹Next · Starbucks Corporation (SBUX) — XLY Consumer Discretionary · S&P 500 Profile |星巴克介紹

Entered 2026-10-30 05:10 · updated 2026-11-15 00:05 · rev 6